MiMedx Group (MDXG), a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare.
MDXG processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. The company's proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications; OrthoFlo, an amniotic fluid-derived allograft for homologous applications; Physio, a bone grafting material comprising 100% bone tissue with no added carrier; and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair.
MDXG also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue; AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process; and AmnioFill, a cellular tissue matrix allograft that enhances healing.
Its products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry.
MiMedx Group, Inc. is headquartered in Marietta, Georgia.
January 3, 2023
RegMed Investors’ (RMi) closing bell: 2023 first session of pain as recessionary perceptions initiated sudden decline
December 22, 2022
RegMed Investors’ (RMi) closing bell: selling returned Thursday
December 9, 2022
RegMed Investors’ (RMi) closing bell: the bleed keeps spraying
December 8, 2022
RegMed Investors’ (RMi) closing bell: sector share pricing rise, not due to investors but, electronic trading and algorithms
December 1, 2022
RegMed Investors’ (RMi) closing bell: hitting the brakes as December begins
November 18, 2022
RegMed Investors’ (RMi) closing bell: this week the cell and gene therapy sector equities got “whacked’ on the knuckles, today it got a pat on the back!
November 17, 2022
RegMed Investors’ (RMi) closing bell: skipping stones and stocks
November 15, 2022
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector gains held fast against PPI and Poland missile strike
November 14, 2022
RegMed Investors’ (RMi) closing bell: the speed bumps slow the action
November 8, 2022
RegMed Investors’ (RMi) closing bell: after five (5) down sessions, it was inevitable that the algorithms would “rule”
35 companies, 1 interpreter!
Insight, foresight and recommendation
MiMedx Group (MDXG) – opened 2018 at $12.98, trooped in February to $17.13 and dropped to $8.75 with a slight rebound to $9.00 on 2/21 after 2/20's shares were halted in premarket trade on news that the company is delaying the release of Q4/17 and full-year ‘17 earnings to conduct an accounting review. The audit committee has hired legal and accounting advisers to conduct an internal investigation of allegations relating to sales and distribution practices..Executives are reviewing the accounting treatment of certain distributor contracts, among other items. "The company believes, based on information available to date, that the outcome of such investigation should not have a material impact on revenue guidance for 2018," said a statement. The company had about $33 million in cash and cash equivalents at year-end and has no debt. Shares have gained 75% in the last 12 months through Friday. Amid buzz is a short seller’s visit by the FBI, MDXG has been involved in a nasty relationship with short sellers that recently took a turn for the worse. Now, MDXG’s internal investigation is delaying the release of its financial results, including its annual statement that would detail last year’s performance - a serious hiccup yet still will be a performer after the clean-up
buyMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.